Mechanisms of resistance to daratumumab in patients with multiple myeloma

IF 2.7 4区医学 Q2 PHARMACOLOGY & PHARMACY

Basic & Clinical Pharmacology & Toxicology Pub Date : 2024-08-26 DOI:10.1111/bcpt.14054

Katrine Fladeland Iversen

引用次数: 0

Abstract

Multiple myeloma (MM) is an incurable cancer in the bone marrow. The treatment of MM has developed significantly during the last 20 years, which has resulted in increased survival. Daratumumab is the first CD38 antibody approved for the treatment of MM. It has improved the treatment of MM even further. This is an evaluation of the modes of action of daratumumab and a description of the development of resistance with a focus on inhibitory checkpoint receptors on CD8⁺ T-cells, complement activation and extracellular vesicles.

Abstract Image

查看原文本刊更多论文

多发性骨髓瘤患者对达拉单抗产生耐药性的机制。

多发性骨髓瘤（MM）是一种无法治愈的骨髓癌。在过去的 20 年里，多发性骨髓瘤的治疗有了长足的发展，从而提高了患者的生存率。达拉单抗是首个获准用于治疗多发性骨髓瘤的 CD38 抗体。它进一步改善了 MM 的治疗。本文评估了达拉土单抗的作用模式，并描述了耐药性的产生，重点是 CD8+ T 细胞上的抑制性检查点受体、补体活化和细胞外囊泡。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Basic & Clinical Pharmacology & Toxicology 医学-毒理学

CiteScore

5.60

自引率

6.50%

发文量

126

审稿时长

1 months

期刊介绍： Basic & Clinical Pharmacology and Toxicology is an independent journal, publishing original scientific research in all fields of toxicology, basic and clinical pharmacology. This includes experimental animal pharmacology and toxicology and molecular (-genetic), biochemical and cellular pharmacology and toxicology. It also includes all aspects of clinical pharmacology: pharmacokinetics, pharmacodynamics, therapeutic drug monitoring, drug/drug interactions, pharmacogenetics/-genomics, pharmacoepidemiology, pharmacovigilance, pharmacoeconomics, randomized controlled clinical trials and rational pharmacotherapy. For all compounds used in the studies, the chemical constitution and composition should be known, also for natural compounds.